

**Policy: MP100**

**Section: Medical Benefit Policy**

**Subject: Cardiac Monitoring by Thoracic Electrical Bioimpedance**

### Applicable Lines of Business

<b>Commercial</b>	<b>X</b>	<b>CHIP</b>	<b>X</b>
<b>Medicare</b>	<b>X</b>	<b>ACA</b>	<b>X</b>
<b>Medicaid</b>	<b>X</b>		

### I. Policy: Cardiac Monitoring by Thoracic Electrical Bioimpedance

#### II. Purpose/Objective:

To provide a policy of coverage regarding Cardiac Monitoring by Thoracic Electrical Bioimpedance

#### III. Responsibility:

- A. Medical Directors
- B. Medical Management

#### IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

#### V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards of good medical treatment practiced by the general medical community.
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

#### Medicaid Business Segment

Medically Necessary — A service, item, procedure, or level of care that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.
- Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an illness, condition, injury or disability.

- Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age.

**DEFINITION:**

Thoracic Electrical Bioimpedance (TEB) is a non-invasive method of measuring cardiac output based on detection of changes in impedance caused by the electrical conductivity of blood that occurs as blood is pumped into the aorta. The procedure is intended as an alternative to invasive cardiac output measurement techniques.

**MEDICARE/MEDICAID BUSINESS SEGMENTS (NCD 20.16)**

**INDICATIONS: Coverage limited to Medicare and Medicaid Business Segment per the applicable CMS Mandates.**

Covered Indications:

- a. Differentiation of cardiogenic from pulmonary causes of acute dyspnea when medical history, physical examination, and standard assessment tools provide insufficient information, and the treating physician has determined that TEB hemodynamic data are necessary for appropriate management of the insured individual.
- b. Optimization of atrioventricular (A/V) interval for insured individuals with A/V sequential cardiac pacemakers when medical history, physical examination, and standard assessment tools provide insufficient information, and the treating physician has determined that TEB hemodynamic data are necessary for appropriate management of the patient.
- c. Monitoring of continuous inotropic therapy for insured individuals with terminal congestive heart failure, when those patients have chosen to die with comfort at home, or for patients waiting at home for a heart transplant.
- d. Evaluation for rejection in insured individuals with a heart transplant as a predetermined alternative to a myocardial biopsy. Medical necessity must be documented should a biopsy be performed after TEB.
- e. Optimization of fluid management in patients with congestive heart failure when medical history, physical examination, and standard assessment tools provide insufficient information, and the treating physician has determined that TEB hemodynamic data are necessary for appropriate management of the insured individual.

**LIMITATIONS:**

1. TEB is not covered when used to treat individuals with:
  - a. Documented evidence of proven or suspected disease involving severe regurgitation of the aorta;
  - b. With minute ventilation (MV) sensor function pacemakers, since the device may adversely affect the functioning of that type of pacemaker;
  - c. During cardiac bypass surgery; or
  - d. In the management of all forms of hypertension with the exception of drug resistant hypertension
2. All other uses of TEB not otherwise specified are not covered.
3. Regardless of the number of measurements to monitor acute interventions, Medicare and Medicaid will reimburse this service once per day.
4. Procedure must be ordered by the treating physician, and that physician must document that its use aids in the management of the patient.
5. The service will not be payable when used for monitoring during anesthesia or other diagnostic or therapeutic procedure.

**EXCLUSIONS:**

There is insufficient published peer reviewed medical literature to support the efficacy of thoracic electrical bioimpedance for cardiac monitoring. For all lines of business except Medicare and Medicaid, thoracic electrical bioimpedance is considered **experimental, investigational or unproven**. The benefit for Medicare and Medicaid members will be in accordance to CMS mandated coverage as outlined in the current coverage determination.

## Medicaid Business Segment:

Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis.

**Note:** A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven is outlined in MP 15 - Experimental Investigational or Unproven Services or Treatment.

**CODING ASSOCIATED WITH:** Cardiac Monitoring by Thoracic Electrical Bioimpedance

*The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services.*

CPT/HCPCS Codes

93701 Bioimpedance, thoracic, electrical

Current Procedural Terminology (CPT®) © American Medical Association: Chicago, IL

### LINE OF BUSINESS:

**Eligibility and contract specific benefits, limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For Medicare, applicable LCD's and NCD's will supercede this policy. For PA Medicaid Business segment, this policy applies as written.**

### REFERENCES:

Winifred B. Hayes, Hayes Inc. Online. Electrical Bioimpedance for the Measurement of Cardiac Output. 1/8/03. Retrieved 2/26/03. Updated 1/10/05.

Shoemaker WC, Belzberg H, Wo CCJ, et al. Multicenter study of noninvasive monitoring systems as alternatives to invasive monitoring of acutely ill emergency patients. *Chest*. 1998;114(6):1643-1652.

Handelsman H. *Measuring Cardiac Output by Electrical Bioimpedance*. Rockville, MD; U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. Health Technology Assessment Report 1001. No. 6. AHCPR Publication Number 92-0073. 1992.

Centers for Medicare & Medicaid Services (CMS) [Web site]. National Coverage Determination (NCD) for Cardiac Output Monitoring by Thoracic Electrical Bioimpedance (TEB) (20.16) - covered. Updated December 2006

<http://www.cms.gov/medicare-coverage-database/details/ncd> Accessed 7/22/15.

American College of Cardiology (ACC) [Web site]. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. 2001. Available at: <http://www.acc.org/clinical/guidelines/failure/iii%5Fassessment.htm>.

Guijar AR, Muralidhar K, et al. Transthoracic electrical bioimpedance cardiac output: Comparison with multigated equilibrium radionuclide cardiography. *J Clin Monit Comput*. 2010;24(2):155-159

Sharma V, Singh A, et al. Comparison of transthoracic electrical bioimpedance cardiac output measurement with thermodilution method in post coronary artery bypass graft patients. *Ann Card Anaesth*. 2011 May-Aug;14(2):104-10

Jermyn, R., Alam, A., Kvasic, J., Saeed, O., and Jorde, U. Hemodynamic-guided heart-failure management using a wireless implantable sensor: Infrastructure, methods, and results in a community heart failure disease-management program. *Clinical Cardiology*, 2017;40: 170-176.

Joosten A, Desebbe O, Suehiro K, et al. Accuracy and precision of non-invasive cardiac output monitoring devices in perioperative medicine: A systematic review and meta-analysis. *Br J Anaesth*. 2017;118(3):298-310

Sanders M, Servaas S, Slagt C. Accuracy and precision of non-invasive cardiac output monitoring by electrical cardiometry: a systematic review and meta-analysis. *J Clin Monit Comput*. 2019 Jun 7.

Kurpaska M, Krzesiński P, Gielerak G, et al. Exercise impedance cardiography reveals impaired hemodynamic responses to exercise in hypertensives with dyspnea. *Hypertens Res.* 2019 Feb;42(2):211-222

Saugel B, Cecconi M, Hajjar LA. Noninvasive Cardiac Output Monitoring in Cardiothoracic Surgery Patients: Available Methods and Future Directions. *J Cardiothorac Vasc Anesth.* 2019 Jun;33(6):1742-1752

Massari F, Scicchitano P, Ciccone MM, ET AL. Bioimpedance vector analysis predicts hospital length of stay in acute heart failure. *Nutrition.* 2019 May;61:56-60.

Sato M, Inai K, Shimizu M. et. al. Bioelectrical impedance analysis in the management of heart failure in adult patients with congenital heart disease. *Congenit Heart Dis* 2019 Mar 14 (2): 167-175

Wang L, Lu Y, Wang H, et al. Effectiveness of an impedance cardiography guided treatment strategy to improve blood pressure control in a real-world setting: results from a pragmatic clinical trial. *Open Heart.* 2021 Sep;8(2):e001719

Mansfield RC, Kaza N, Charalambous A, et al. Cardiac output measurement in neonates and children using noninvasive electrical bioimpedance compared with standard methods: A systematic review and meta-analysis. *Crit Care Med.* 2022;50(1):126-137

Krzesiński P, Jankowska EA, Siebert J, et al. Effects of an outpatient intervention comprising nurse-led non-invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure (AMULET study): a randomised controlled trial. *Eur J Heart Fail.* 2022 Mar;24(3):565-577.

Centers for Medicare & Medicaid Service. NCD 20.16 Cardiac Output Monitoring by Thoracic Electrical Bioimpedance (TEB)

This policy will be revised as necessary and reviewed no less than annually.

**Devised:** 03/03

**Revised:** 2/04 (CMS Coverage Determination); 7/04 (drop prior auth); 7/05 (update reference);7/06 (limitations/coding);7/07 (updated indications and Limitation section); 7/08, 7/15 (revised Limitations) , 6/24 (Add NCD)

**Reviewed:** 7/09, 7/10, 7/11, 7/12, 7/13, 7/14, 7/16, 6/17, 6/18, 6/19, 6/20, 6/21, 6/22, 6/23

**CMS UM Oversight Committee Approval:** 12/23, 7/24

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at <https://www.geisinger.org/health-plan/providers/ghp-clinical-policies>

Please be advised that the use of the logos, service marks or names of Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company on a marketing, press releases or any communication piece regarding the contents of this medical policy is strictly prohibited without the prior written consent of Geisinger Health Plan. Additionally, the above medical policy does not confer any endorsement by Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company regarding the medical service, medical device or medical lab test described under this medical policy.